deoxycholic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4988 83-44-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • choleic acid
  • deoxycholate
  • sodium deoxycholate
  • deoxycholic acid
  • kybella
  • ATX-101
  • dihydroxycholanoic acid
  • desoxycholic acid
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
  • Molecular weight: 392.58
  • Formula: C24H40O4
  • CLOGP: 4.51
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.35
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 29, 2015 FDA KYTHERA BIOPHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site swelling 233.50 93.58 67 892 41706 50562459
Facial paresis 208.13 93.58 38 921 3114 50601051
Injection site nodule 149.13 93.58 29 930 3319 50600846
Swelling 128.17 93.58 66 893 200806 50403359
Injection site pain 128.09 93.58 55 904 110969 50493196
Nerve injury 117.49 93.58 28 931 8322 50595843
Injection site induration 96.84 93.58 24 935 8373 50595792

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site swelling 174.37 82.00 46 578 41307 64456801
Facial paresis 119.76 82.00 23 601 4869 64493239
Swelling 92.79 82.00 40 584 160178 64337930
Injection site pain 88.83 82.00 35 589 111373 64386735
Injection site nodule 84.05 82.00 16 608 3214 64494894

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AX24 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
FDA PE N0000008476 Decreased Cell Membrane Integrity
MeSH PA D002756 Cholagogues and Choleretics
MeSH PA D005765 Gastrointestinal Agents
FDA EPC N0000191548 Cytolytic Agent
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:85234 human blood serum metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Excess subcutaneous fat indication 248302001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.92 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 8846066 Feb. 8, 2025 METHOD FOR REDUCTION OF SUBMENTAL FAT
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 8298556 Aug. 3, 2025 METHOD FOR REDUCTION OF SUBMENTAL FAT
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 7622130 Dec. 10, 2027 METHOD FOR REDUCTION OF SUBMENTAL FAT
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 7754230 Dec. 10, 2027 METHOD FOR REDUCTION OF SUBMENTAL FAT
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 8546367 Feb. 21, 2028 METHOD FOR REDUCTION OF SUBMENTAL FAT
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 9522155 Feb. 21, 2028 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 9636349 Feb. 21, 2028 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
20MG/2ML (10MG/ML) KYBELLA KYTHERA BIOPHARMS N206333 April 29, 2015 RX SOLUTION SUBCUTANEOUS 9949986 Feb. 21, 2028 IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
fMet-Leu-Phe receptor GPCR ANTAGONIST Ki 4 IUPHAR
Bile acid receptor Nuclear hormone receptor EC50 4.35 CHEMBL
G-protein coupled bile acid receptor 1 GPCR AGONIST EC50 6.20 IUPHAR
Steroid Delta-isomerase Unclassified Kd 4.80 CHEMBL

External reference:

IDSource
005990WHZZ UNII
4018928 VANDF
4035848 VANDF
C0011479 UMLSCUI
CHEBI:28834 CHEBI
DHO PDB_CHEM_ID
CHEMBL406393 ChEMBL_ID
222528 PUBCHEM_CID
DB03619 DRUGBANK_ID
CHEMBL412272 ChEMBL_ID
CHEMBL1208257 ChEMBL_ID
CHEMBL514674 ChEMBL_ID
D003840 MESH_DESCRIPTOR_UI
9540 INN_ID
610 IUPHAR_LIGAND_ID
DB05780 DRUGBANK_ID
1367220 RXNORM
14975 MMSL
234529 MMSL
d08364 MMSL
434444004 SNOMEDCT_US
781373006 SNOMEDCT_US
78258003 SNOMEDCT_US
CHEMBL453873 ChEMBL_ID
001205 NDDF
010267 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KYBELLA HUMAN PRESCRIPTION DRUG LABEL 1 61168-101 INJECTION, SOLUTION 20 mg SUBCUTANEOUS NDA 27 sections